Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 7,083 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Cancer
Interventions: Aldesleukin, Sargramostim, therapeutic autologous lymphocytes; Biological
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Solid Tumors
Interventions: INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more

Conditions: Breast Cancer, Ovarian Cancer, Gynecologic Neoplasm, Endometrial Cancer
Interventions: Paxman Scalp Cooling Device; Device
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Art Therapy, Music Therapy; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Metastatic Breast Cancer
Interventions: Not listed
Lead sponsor: Health Outcomes Solutions; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Winter Park, Florida

Conditions: Metastatic Breast Cancer
Interventions: Not listed
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Aerobic Exercise, Early Stage Triple Negative Breast Cancer
Interventions: Exercise; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, CLL
Interventions: Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: filgrastim, capecitabine, celecoxib, cyclophosphamide, docetaxel, doxorubicin hydrochloride, gene expression analysis, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, imaging biomarker analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacogenomic studies, dynamic contrast-enhanced magnetic resonance imaging, needle biopsy, neoadjuvant therapy, radiomammography, ultrasound imaging; Biological · Drug · Genetic + 2 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Breast Cancer
Interventions: Lovastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Neoplasms, Breast
Interventions: pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg, pazopanib (GW786034) 800 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 19
States / cities: Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more

Conditions: Breast Cancer
Interventions: Patient-Participation Aid; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Tampa, Florida • Shreveport, Louisiana

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 38
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more

Conditions: Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Amifostine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 15
States / cities: Decatur, Illinois • Urbana, Illinois • Wichita, Kansas + 12 more

Conditions: Brain Metastases
Interventions: Whole brain radiation, Stereotactic radiation (SRS); Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer
Interventions: Capecitabine, Docetaxel; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Breast Cancer
Interventions: microarray analysis, breast biopsy; Genetic · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer, Urothelial Carcinoma
Interventions: Trastuzumab deruxtecan, Nivolumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more

Conditions: Breast Cancer
Interventions: trastuzumab, paclitaxel; Biological · Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Bethesda, Maryland • Morgantown, West Virginia

Conditions: Breast Neoplasms
Interventions: Afatinib once daily (OD), Vinorelbine Weekly; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • Durham, North Carolina

Conditions: Aromatase Inhibitor, Musculoskeletal Symptoms, Postmenopausal Breast Cancer Survivors
Interventions: APA, Sham APA control, Education control; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Gemcitabine, Carboplatin, Herceptin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Interventions: ABBV-400, Itraconazole (ITZ), Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 20
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 15 more

Search by objective public record fields.

Biological Therapy in Treating Women With Stage IV Breast Cancer

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer

Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer

Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC

Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC

A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers

Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2

Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings

A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400